BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28465370)

  • 1. Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.
    Cao J; Ji D; Chen Z; Shen W; Wang J; Li B; Chi H; Long A; Gao L; Li J
    Oncologist; 2017 Jun; 22(6):638-e56. PubMed ID: 28465370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
    Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
    Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
    Ueda S; Satoh T; Gotoh M; Gao L; Doi T
    Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
    Aftimos P; Rolfo C; Rottey S; Offner F; Bron D; Maerevoet M; Soria JC; Moshir M; Dreier T; Van Rompaey L; Michot JM; Silence K; Hultberg A; Gandini D; de Haard H; Ribrag V; Peeters M; Thibault A; Leupin N; Awada A
    Clin Cancer Res; 2017 Nov; 23(21):6411-6420. PubMed ID: 28765328
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
    Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
    Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
    J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
    Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR
    Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors.
    Nokihara H; Yamamoto N; Yamada Y; Honda K; Asahina H; Tamura Y; Hozak RR; Gao L; Suzukawa K; Enatsu S; Tamura T
    Jpn J Clin Oncol; 2017 Apr; 47(4):298-305. PubMed ID: 28158463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
    Jimeno A; Gordon M; Chugh R; Messersmith W; Mendelson D; Dupont J; Stagg R; Kapoun AM; Xu L; Uttamsingh S; Brachmann RK; Smith DC
    Clin Cancer Res; 2017 Dec; 23(24):7490-7497. PubMed ID: 28954784
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
    Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
    Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
    Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.
    Haluska P; Menefee M; Plimack ER; Rosenberg J; Northfelt D; LaVallee T; Shi L; Yu XQ; Burke P; Huang J; Viner J; McDevitt J; LoRusso P
    Clin Cancer Res; 2014 Sep; 20(18):4747-57. PubMed ID: 25024259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
    Sessa C; Lorusso P; Tolcher A; Farace F; Lassau N; Delmonte A; Braghetti A; Bahleda R; Cohen P; Hospitel M; Veyrat-Follet C; Soria JC
    Clin Cancer Res; 2013 Sep; 19(17):4832-42. PubMed ID: 23833302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
    Pilbeam KL; Pradhan K; Croop J; Minard CG; Liu X; Voss SD; Isikwei E; Berg SL; Reid JM; Fox E; Weigel BJ
    Pediatr Blood Cancer; 2024 Mar; 71(3):e30817. PubMed ID: 38189770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
    Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
    Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.
    Calvo E; Soria JC; Ma WW; Wang T; Bahleda R; Tolcher AW; Gernhardt D; O'Connell J; Millham R; Giri N; Wick MJ; Adjei AA; Hidalgo M
    Clin Cancer Res; 2017 Mar; 23(5):1177-1185. PubMed ID: 27733479
    [No Abstract]   [Full Text] [Related]  

  • 19. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
    Hong DS; Hui D; Bruera E; Janku F; Naing A; Falchook GS; Piha-Paul S; Wheler JJ; Fu S; Tsimberidou AM; Stecher M; Mohanty P; Simard J; Kurzrock R
    Lancet Oncol; 2014 May; 15(6):656-66. PubMed ID: 24746841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
    Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.